112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders

HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

Key Highlights:

• Sepsis & NETosis Validation: Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic shock patients. $7.3 million government-backed DETECSEPS program in France due to start recruitment in September 2026.
• Demonstrates Clinical Utility of Breakthrough Finger-Prick Detection of Nucleosomes: Expanding global market potential for sepsis testing using lateral flow, thereby potentially greatly expanding the addressable market and utility.
• European Lung Cancer Reimbursement: Plans formal conditional reimbursement submission in France by the end of 2026 to enable routine clinical use.
• First Half Revenue Growth: Reported $1.4M of revenue in the first half of 2026, representing a 112% increase year-over-year.
• Feline Lymphoma Manuscript Submission: Submitted for publication the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated subsequent to publication.
• Global Licensing Momentum: Confirms active discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies, including for technical evaluations.
• Newly Announced Collaboration: successfully transferred Volition Nu.Q® NETs assay onto Sysmex Corporation's platform, in preparation for anticipated broader agreement. Sysmex Corporation is a multi-billion dollar market capitalization company listed on the Tokyo Stock Exchange.
• Capture-Seq™ Platform: Peer-reviewed paper published: validation cohort detected over 95% of Stage I and II cancers, Underscores a $23 billion annualized opportunity in cancer detection.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.